The selection, dosing, and administration of anti-cancer agents and the management of associated toxicities are complex. Drug dose modifications and schedule and initiation of supportive care interventions are often necessary because of expected toxicities and because of individual patient variability, prior treatment, and comorbidities. Thus, the optimal delivery of anti-cancer agents requires a healthcare delivery team experienced in the use of such agents and the management of associated toxicities in patients with cancer. The chemotherapy regimens below may include both FDA-approved and unapproved uses/regimens and are provided as references only to the latest treatment strategies. Clinicians must choose and verify treatment options based on the individual patient.

### GENERAL TREATMENT NOTES
- Chemotherapy regimens for endometrioid histologies, papillary serous carcinoma, or clear cell carcinoma; some agents can be used for carcinosarcoma as indicated. Multi-agent regimens preferred, if tolerated.
- Participation in clinical trial strongly recommended.
- Regimens denoted with an * or † are considered by the NCCN as Category 1, which means the recommendations are based on high-level evidence (i.e., randomized controlled trials) and there is uniform NCCN consensus.
- Hormone therapy for metastatic disease consists mainly of progesterational agents. Tamoxifen and aromatase inhibitors are also been investigated. Thus far, no particular drug, dose or schedule has been found to be superior. 

### REGIMEN DOSING

#### CHEMOTHERAPY REGIMENS

**Cisplatin (Platinol; CDDP) + doxorubicin (Adriamycin)***  
**Day 1:** Doxorubicin 45mg/m² IV + cisplatin 50mg/m² IV, then  
**Day 2-11:** Optional filgrastim 5mcg/kg/day  
Repeat cycle every 21 days; maximum 6 cycles

**Cisplatin + doxorubicin + paclitaxel (Taxol)**  
**Day 1:** Doxorubicin 45mg/m² IV + cisplatin 50mg/m² IV, then  
**Day 2:** Paclitaxel 160mg/m² 3-hr IV infusion, then  
**Day 3-12:** Filgrastim 5mcg/kg SC  
Repeat cycle every 21 days for max 7 cycles

**Ifosfamide (Ifex) + paclitaxel†**  
**Day 1:** Paclitaxel 135mg/m² administered as a 3-hr IV infusion, plus  
**Days 1-3:** Ifosfamide 1.6g/m²/day IV (1.2g/m²/day if patient received prior radiation)  
Repeat cycle every 21 days for 8 cycles

**Carboplatin (Paraplatin) + paclitaxel**  
**Day 1:** Carboplatin AUC=6mg/mL/min IV + paclitaxel 175mg/m² IV  
Repeat cycle every 21 days

**CIM (cisplatin + ifosfamide + mesna) for carcinosarcoma**  
**Days 1-4:** Cisplatin 20mg/m²/day IV + ifosfamide 1.5g/m²/day 1-hr IV infusion  
**Day 1:** Mesna 120mg/m² IV bolus (loading dose), then  
**Days 2-4:** Mesna 1.5g/m²/day continuous IV infusion  
Repeat cycle every 21 days for 3 cycles

#### HORMONAL REGIMENS (FOR ENDOMETRIOID HISTOLOGIES ONLY)

**Tamoxifen (Nolvadex)**  
Tamoxifen 20mg orally twice daily

**Medroxyprogesterone acetate (MPA)**  
Medroxyprogesterone acetate 200mg orally once daily until toxicity or disease progression

**Tamoxifen + medroxyprogesterone acetate**  
Medroxyprogesterone acetate 80mg orally twice daily for 21 days alternating with tamoxifen 20mg orally twice daily  
Repeat cycle every 21 days

### REFERENCES